Bioavailability Study of Donepezil Hydrochloride Tablets 23 mg Under Fed Condition

NCT ID: NCT01923259

Last Updated: 2013-08-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 94 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-10-31
• Study Completion Date: 2010-12-31

Brief Summary

To evaluate and compare the relative bioavailability and therefore the bioequivalence of two different formulations of donepezil after a single oral dose administration under fed conditions.

Detailed Description

Single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence, crossover study under fed conditions.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Donepezil Hydrochloride Tablets, 23 mg

Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd

Group Type: EXPERIMENTAL

Donepezil

Intervention Type: DRUG

Donepezil Hydrochloride tablets,23 mg

Aricept

Aricept® 23 mg tablet of Eisai Inc

Group Type: ACTIVE_COMPARATOR

Donepezil

Intervention Type: DRUG

Donepezil Hydrochloride tablets,23 mg

Interventions

Donepezil

Donepezil Hydrochloride tablets,23 mg

Intervention Type: DRUG

Other Intervention Names

Aricept

Eligibility Criteria

Inclusion Criteria

1. Male or female volunteer

2. Volunteer aged of at least 18 years but not older than 45 years

3. Volunteer with a body mass index (BMI) greater than or equal to 21 and below 30 kg/m2

4. Volunteer with a body weight greater than or equal to 60 kg.

5. Light-, non- or ex-smokers. A light smoker is defined as someone smoking 10 cigarettes or less per day for at least 3 months before day 1 of this study. An ex-smoker is defined as someone who completely stopped smoking for at least 12 months before day 1 of this study.

6. Availability for the entire study period

7. Motivated volunteer and absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; ability to cooperate adequately; ability to understand and observe the instructions of the physician or designee.

8. Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance

9. Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination and/or clinical laboratory evaluations (hematology, biochemistry, ECG and urinalysis)

10. Willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the volunteer

Exclusion Criteria

1. Seated pulse rate less than 50 bpm at screening

2. Seated blood pressure below 105/60 mmHg at screening

3. Seated blood pressure below 105/60 mmHg before drug administration

4. Females who are pregnant or are lactating

5. Females of childbearing potential who refuse to use an acceptable contraceptive regimen throughout the entire duration of the study

6. History of significant hypersensitivity to donepezil, piperidine derivatives, scopolamine, or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs

7. Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects

8. History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability

9. Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease

10. Suicidal tendency, history of or disposition to seizures, state of confusion,clinically relevant psychiatric diseases

11. Presence of out-of-range cardiac interval (PR < 110 msec, PR > 200 msec, QRS >110 msec and QTc > 440 msec) on the screening ECG or other clinically significant ECG abnormalities.

12. Use of ASA or NSAIDs (or any product containing ASA or NSAIDs) in the previous 7 days before day 1 of this study

13. Use of diphenhydramine in the previous 10 hours before day 1 of this study

14. Known presence of rare hereditary problems of galactose and /or lactose intolerance

15. Known presence of glaucoma or a predisposition to angle-closure glaucoma

16. Maintenance therapy with any drug, or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)

17. Any clinically significant illness in the previous 28 days before day 1 of this study

18. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and St John's Wort), in the previous 28 days before day 1 of this study

19. Any history of tuberculosis and/or prophylaxis for tuberculosis

20. Positive urine screening of alcohol and/or drugs of abuse

21. Positive results to HIV, HBsAg or anti-HCV tests

22. Females who are pregnant according to a positive serum pregnancy test

23. Volunteers who took an Investigational Product (in another clinical trial) or donated 50 mL or more of blood in the previous 28 days before day 1 of this study.

24. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Dr. Reddy's Laboratories Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Eric Sicard, MD

Role: PRINCIPAL_INVESTIGATOR

Algorithme Pharma Inc

Locations

Algorithme Pharma Inc.

Mount Royal, Quebec, Canada

Countries

Canada

Other Identifiers

DNI-P0-653

Identifier Type: -

Identifier Source: org_study_id